Penbraya
Payments companies reported to CMS as associated with Penbraya. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Penbraya, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Penbraya
These are the largest totals companies reported as associated with Penbraya. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jana Shaw | Watertown, NY | Pediatric Infectious Diseases | $91,771.70 |
| Jaime Fergie | Corpus Christi, TX | Pediatric Infectious Diseases | $62,380.91 |
| Ruth Carrico | Chicago, IL | Family | $32,662.55 |
| Gary Marshall | Louisville, KY | Pediatric Infectious Diseases | $21,554.20 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $15,714.79 |
| Stephanie Hanenberg | Colorado Springs, CO | Family | $14,526.22 |
| James Conway | Madison, WI | Pediatric Infectious Diseases | $12,965.49 |
| Tamera Coyne-Beasley | Birmingham, AL | Pediatrics | $11,549.18 |
| Jocelyn Ang | Detroit, MI | Pediatric Infectious Diseases | $10,769.43 |
| Arthur Jeng | Sylmar, CA | Infectious Disease | $10,585.99 |
Prescribed Penbraya?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.